Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells

Stem Cells International
Nataliya PetinatiValery Savchenko

Abstract

Multipotent mesenchymal stromal cells (MSCs) participate in the formation of bone marrow niches for hematopoietic stem cells. Donor MSCs can serve as a source of recovery for niches in patients with graft failure (GF) after allogeneic bone marrow (BM) transplantation. Since only few MSCs reach the BM after intravenous injection, MSCs were implanted into the iliac spine. For 8 patients with GF after allo-BMT, another hematopoietic stem cell transplantation with simultaneous implantation of MSCs from their respective donors into cancellous bone was performed. BM was aspirated from the iliac crest of these patients at 1-2, 4-5, and 9 months after the intraosseous injection of donor MSCs. Patients' MSCs were cultivated, and chimerism was determined. In 6 out of 8 patients, donor hematopoiesis was restored. Donor cells (9.4 ± 3.3%) were detected among MSCs. Thus, implanted MSCs remain localized at the site of administration and do not lose the ability to proliferate. These results suggest that MSCs could participate in the restoration of niches for donor hematopoietic cells or have an immunomodulatory effect, preventing repeated rejection of the graft. Perhaps, intraosseous implantation of MSCs contributes to the success of the seco...Continue Reading

References

Jan 1, 1986·International Review of Cytology·J L Chertkov
Jun 1, 1997·British Journal of Haematology·S A KuznetsovP G Robey
Mar 24, 1998·Bone Marrow Transplantation·H HägglundP Aspelin
May 14, 2005·Blood·Tsvee LapidotOrit Kollet
Feb 29, 2008·Journal of Molecular and Cellular Cardiology·Emmanouil ChavakisStefanie Dimmeler
Jul 11, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mei GuoHuisheng Ai
Aug 13, 2010·Nature·Simón Méndez-FerrerPaul S Frenette
Jul 8, 2011·Stem Cells and Development·Marijke W MaijenburgCarlijn Voermans
Jan 14, 2012·Stem Cells International·Larisa A KuzminaValery G Savchenko
Dec 12, 2012·Bone Marrow Transplantation·R OlssonO Ringden
Jan 10, 2013·Annual Review of Immunology·Paul S FrenetteChristoph Scheiermann
Jul 25, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yuan KongXiao-Jun Huang
Mar 4, 2014·Stem Cells·Malte von Bonin, Martin Bornhäuser
Sep 23, 2014·Bone Marrow Transplantation·H HägglundO Ringden
Dec 11, 2014·The Journal of Biological Chemistry·Jing-Xian YangQing-Ping Wen
Feb 25, 2015·Stem Cells and Cloning : Advances and Applications·Greg AsatrianBruno Peault
Jun 27, 2015·European Journal of Haematology·Larisa A KuzminaValery G Savchenko
Oct 16, 2015·Blood·Laura M Calvi, Daniel C Link
Oct 4, 2016·Frontiers in Immunology·Stavroula Masouridi-LevratYves Chalandon
Mar 21, 2017·Stem Cells·Franziska NitzscheJohannes Boltze

❮ Previous
Next ❯

Citations

Sep 29, 2020·Stem Cells and Cloning : Advances and Applications·Gashaw DessieBirhanu Ayelign
Nov 26, 2019·Biochemistry. Biokhimii︠a︡·N V Bogatcheva, M E Coleman

❮ Previous
Next ❯

Methods Mentioned

BETA
bone marrow collection

Clinical Trials Mentioned

NCT03389919

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.